SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Mechanism: ftd-tdp-pathology

mechanism 4,657 words KG: ent-dise-39c8f1c5

Contents

ftd-tdp-pathology

⚙ Mechanism Info

Name	ent-dise-39c8f1c5

Knowledge Graph

Related Hypotheses (11)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36 Cryptic Exon Silencing Restoration
Score: 0.46 Cross-Seeding Prevention Strategy
Score: 0.45 Glycine-Rich Domain Competitive Inhibition
Score: 0.43 VCP-Mediated Autophagy Enhancement
Score: 0.41

Microglial AIM2 Inflammasome as the Primary Driver of TDP-43
Score: 0.60 Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53 Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47 GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52 Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.42 RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37

Related Analyses (30)

How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived

RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed How does APOE4 mechanistically increase TDP-43 pathology fre
neurodegeneration · failed What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What mechanisms underlie TDP-43's contribution to cognitive
neurodegeneration · failed What determines the selectivity and efficiency of intercellu
neurodegeneration · completed What are the specific design principles for small molecules
medicinal chemistry · failed Does DNAJB6 directly inhibit cross-seeding between tau, α-sy
neurodegeneration · failed What is the therapeutic window between insufficient and toxi
neurodegeneration · completed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed

Related Experiments (16)

Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40 FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40

Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40 Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40 Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an
validation · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas